Lithium protects against cartilage degradation in osteoarthritis

Arthritis and Rheumatology

Volumn 66, Issue 5, 2014, Pages 1228-1236

  Minashima, Takeshi ^a,b   Zhang, Ying ^a,b   Lee, Youjin ^a   Kirsch, Thorsten ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE 2; CHONDROITIN SULFATE; COLLAGENASE 3; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LITHIUM CHLORIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEOGLYCAN; STAT3 PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL LYSATE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMUR HEAD; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; KNEE; LUCIFERASE ASSAY; MALE; MOUSE; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN DEPLETION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

AGED; ANIMALS; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMUR HEAD; HUMANS; INTERLEUKIN-1BETA; LITHIUM CHLORIDE; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; NF-KAPPA B; OSTEOARTHRITIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEOGLYCANS; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84899712233     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38373     Document Type: Article

References (44)

1. Goldring MB,. Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. Best Pract Res Clin Rheumatol 2006; 20: 1003-25.
2. Goldring M, Otero M,. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011; 23: 471-8.
3. Hedbom E, Hauselmann HJ,. Molecular aspects of pathogenesis in osteoarthritis: the role of inflammation. Cell Mol Life Sci 2002; 59: 45-53.
4. Kaneko S, Satoh T, Chiba J, Ju C, Inoue K, Kagawa J,. Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther 2000; 6: 71-9.
5. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H,. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011; 7: 33-42.
6. Goodwin FK, Ghaemi SN,. The impact of the discovery of lithium on psychiatric thought and practice in the USA and Europe. Aust N Z J Psychiatry 1999; 33 Suppl: S54-64.
7. Lenox RH, Hahn CG,. Overview of the mechanism of action of lithium in the brain: fifty-year update. J Clin Psychiatry 2000; 61 Suppl 9: 5-15.
8. Lenox RH, Wang L,. Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks. Mol Psychiatry 2003; 8: 135-44.
9. Quiroz JA, Machado-Vieira R, Zarate CA Jr, Manji HK,. Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 2010; 62: 50-60.
10. Williams RS, Harwood AJ,. Lithium therapy and signal transduction. Trends Pharmacol Sci 2000; 21: 61-4.
11. Hui W, Litherland GJ, Jefferson M, Barter MJ, Elias MS, Cawston TE, et al. Lithium protects cartilage from cytokine-mediated degradation by reducing collagen-degrading MMP production via inhibition of the P38 mitogen-activated protein kinase pathway. Rheumatology (Oxford) 2010; 49: 2043-53.
12. Welch ID, Cowan MF, Beier F, Underhill TM,. The retinoic acid binding protein CRABP2 is increased in murine models of degenerative joint disease. Arthritis Res Ther 2009; 11: R14.
13. Campbell KA, Minashima T, Zhang Y, Hadley S, Lee YJ, Giovinazzo J, et al. Annexin A6 interacts with p65 and stimulates NF-κB activity and catabolic events in articular chondrocytes. Arthritis Rheum 2013; 65: 3120-9.
14. Ma HL, Blanchet TJ, Peluso D, Hopkins B, Morris EA, Glasson SS,. Osteoarthritis severity is sex dependent in a surgical mouse model. Osteoarthritis Cartilage 2007; 15: 695-700.
15. Dehpour AR, Sadr SS, Azizi MR, Namiranian K, Farahani M, Javidan AN,. Lithium inhibits the development of physical dependence to clonidine in mice. Pharmacol Toxicol 2002; 90: 89-93.
16. Clement-Lacroix P, Ai M, Morvan F, Roman-Roman S, Vayssiere B, Belleville C, et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A 2005; 102: 17406-11.
17. Chen Y, Whetstone HC, Lin AC, Nadesan P, Wei Q, Poon R, et al. β-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med 2007; 4: e249.
18. Glasson SS, Chambers MG, Van Den Berg WB, Little CB,. The OARSI histopathology initiative-recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage 2010; 18 Suppl 3: S17-23.
19. Merz D, Liu R, Johnson K, Terkeltaub R,. IL-8/CXCL8 and growth-related oncogene α/CXCL1 induce chondrocyte hypertrophic differentiation. J Immunol 2003; 171: 4406-15.
20. Akhtar N, Miller MJ, Haqqi TM,. Effect of a Herbal-Leucine mix on the IL-1β-induced cartilage degradation and inflammatory gene expression in human chondrocytes. BMC Complement Altern Med 2011; 11: 66.
21. Minashima T, Small W, Moss SE, Kirsch T,. Intracellular modulation of signaling pathways by annexin A6 regulates terminal differentiation of chondrocytes. J Biol Chem 2012; 287: 14803-15.
22. Stambolic V, Ruel L, Woodgett JR,. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-8.
23. Harwood AJ,. Prolyl oligopeptidase, inositol phosphate signalling and lithium sensitivity. CNS Neurol Disord Drug Targets 2011; 10: 333-9.
24. Marcu KB, Otero M, Olivotto E, Borzi RM, Goldring MB,. NF-κB signaling: multiple angles to target OA. Curr Drug Targets 2010; 11: 599-613.
25. 2 terminal kinase and p38 by IL-1 and TNF in human articular chondrocytes. J Clin Invest 1996; 98: 2425-30.
26. Shikhman AR, Kuhn K, Alaaeddine N, Lotz M,. N-acetylglucosamine prevents IL-1β-mediated activation of human chondrocytes. J Immunol 2001; 166: 5155-60.
27. Berenbaum F,. Signaling transduction: target in osteoarthritis. Curr Opin Rheumatol 2004; 16: 616-22.
28. Arman A, Auron PE,. Interleukin 1 (IL-1) induces the activation of Stat3. Adv Exp Med Biol 2003; 534: 297-307.
29. Mori T, Miyamoto T, Yoshida H, Asakawa M, Kawasumi M, Kobayashi T, et al. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol 2011; 23: 701-12.
30. Gao H, Ward PA,. STAT3 and suppressor of cytokine signaling 3: potential targets in lung inflammatory responses. Expert Opin Ther Targets 2007; 11: 869-80.
31. Levinger I, Levinger P, Trenerry MK, Feller JA, Bartlett JR, Bergman N, et al. Increased inflammatory cytokine expression in the vastus lateralis of patients with knee osteoarthritis. Arthritis Rheum 2011; 63: 1343-8.
32. 2. PLoS One 2011; 6: e27630.
33. Nieminen R, Korhonen R, Moilanen T, Clark AR, Moilanen E,. Aurothiomalate inhibits cyclooxygenase 2, matrix metalloproteinase 3, and interleukin-6 expression in chondrocytes by increasing MAPK phosphatase 1 expression and decreasing p38 phosphorylation: MAPK phosphatase 1 as a novel target for antirheumatic drugs. Arthritis Rheum 2010; 62: 1650-9.
34. Legendre F, Bogdanowicz P, Boumediene K, Pujol JP,. Role of interleukin 6 (IL-6)/IL-6R-induced signal tranducers and activators of transcription and mitogen-activated protein kinase/extracellular. J Rheumatol 2005; 32: 1307-16.
35. Legendre F, Dudhia J, Pujol JP, Bogdanowicz P,. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of type II collagen, aggrecan core, and link protein transcription in articular chondrocytes: association with a down-regulation of SOX9 expression. J Biol Chem 2003; 278: 2903-12.
36. Doble BW, Woodgett JR,. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116: 1175-86.
37. Corr M,. Wnt-β-catenin signaling in the pathogenesis of osteoarthritis. Nat Clin Pract Rheumatol 2008; 4: 550-6.
38. Lodewyckx L, Lories RJ,. WNT signaling in osteoarthritis and osteoporosis: what is the biological significance for the clinician? Curr Rheumatol Rep 2009; 11: 23-30.
39. Zhu M, Tang D, Wu Q, Hao S, Chen M, Xie C, et al. Activation of β-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult β-catenin conditional activation mice. J Bone Miner Res 2009; 24: 12-21.
40. Namdari S, Wei L, Moore D, Chen Q,. Reduced limb length and worsened osteoarthritis in adult mice after genetic inhibition of p38 MAP kinase activity in cartilage. Arthritis Rheum 2008; 58: 3520-9.
41. Huang CY, Lai KY, Hung LF, Wu WL, Liu FC, Ho LJ,. Advanced glycation end products cause collagen II reduction by activating Janus kinase/signal transducer and activator of transcription 3 pathway in porcine chondrocytes. Rheumatology (Oxford) 2011; 50: 1379-89.
42. Hayden MS, Ghosh S,. Signaling to NF-κB. Genes Dev 2004; 18: 2195-224.
43. Ma B, van Blitterswijk CA, Karperien M,. A Wnt/β-catenin negative feedback loop inhibits interleukin-1-induced matrix metalloproteinase expression in human articular chondrocytes. Arthritis Rheum 2012; 64: 2589-600.
44. Butoescu N, Jordan O, Doelker E,. Intra-articular drug delivery systems for the treatment of rheumatic diseases: a review of the factors influencing their performance. Eur J Pharm Biopharm 2009; 73: 205-18.